CELESTODERM V/2 CREAM

País: Canadà

Idioma: anglès

Font: Health Canada

Compra'l ara

Fitxa tècnica Fitxa tècnica (SPC)
29-09-2020

ingredients actius:

BETAMETHASONE (BETAMETHASONE VALERATE)

Disponible des:

BAUSCH HEALTH, CANADA INC.

Codi ATC:

D07AC01

Designació comuna internacional (DCI):

BETAMETHASONE

Dosis:

0.05%

formulario farmacéutico:

CREAM

Composición:

BETAMETHASONE (BETAMETHASONE VALERATE) 0.05%

Vía de administración:

TOPICAL

Unidades en paquete:

450G

tipo de receta:

Prescription

Área terapéutica:

ANTI-INFLAMMATORY AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0106299002; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2014-10-10

Fitxa tècnica

                                PRESCRIBING INFORMATION
PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.05%
TOPICAL CORTICOSTEROID
September
29
,
2020
DATE OF
REVISION:
Control
#:
242776
H7L 4A8
Laval, Quebec
2150 St-Elzear
Blvd. West
,
BAUSCH HEALTH, CANADA INC.
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 2 of 10_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS…………………………………………………......4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 3 of 10_ PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone val
                                
                                Llegiu el document complet
                                
                            

Documents en altres idiomes

Fitxa tècnica Fitxa tècnica francès 29-09-2020

Cerqueu alertes relacionades amb aquest producte

Veure l'historial de documents